GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis…

Continue ReadingGLP-1 drugs may influence chronic pain through gut-brain and immune pathways

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial…

Continue ReadingAs GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

Forge Nano and Nanexa enter joint development agreement to advance manufacturing for ALD-coated PharmaShell® long-acting injectable medicines

Forge Nano, Inc., a leading U.S.-based semiconductor equipment and advanced materials company pioneering Atomic Layer Deposition ("ALD") technology for artificial intelligence ("AI")-era chip manufacturing and defense battery applications, which has…

Continue ReadingForge Nano and Nanexa enter joint development agreement to advance manufacturing for ALD-coated PharmaShell® long-acting injectable medicines

Advances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases

A review in Cell Reports Medicine examines how advances in oligonucleotide chemistry and delivery have established ASOs and RNA interference therapies as a class of genetic medicines, with 21 oligonucleotides…

Continue ReadingAdvances in chemistry and delivery are taking oligonucleotide medicines beyond rare diseases